Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sits in the top decile of US sponsors by registered trial count (#348 of 15,742 sponsors by registered trial count).
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center: 55 sponsored US clinical trials, 1 recruiting.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sponsors 55 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 46 completed. 16 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is LET, with 1 trials.
Top-decile sponsor footprint
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ranks in the top decile of sponsors by registered trial count (#348 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
46 of 50 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
55 total, page 2 of 2
L-Glutamine Therapy for Sickle Cell Anemia
NCT00586209
Dietary Protein Requirements in Hemodialysis Patients
NCT02194114
Arterial pH and Total Body Nitrogen Balances in APD
NCT00586131
A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers
NCT00386958
The Significance of Funguria in Hospitalized Patients
NCT00787085
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 12 |
| Phase 3 | 4 |
| Phase 4 | 12 |
Therapeutic Areas
What is open in the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center pipeline
1 recruiting of 55 indexed (2% open); 46 completed (84%).
Phase mix: 16 late (III/IV) vs 19 early (I/II) (balanced across stages).
Top condition: LET (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center: open-pipeline peers nationwide
Peers matched on 55 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 55 trials (± recruiting share)
- Connecticut Children's Medical Center · 55 trials · 27% recruiting
- Radicle Science · 55 trials · 7% recruiting
- Lexicon Pharmaceuticals · 56 trials · 2% recruiting
- AdventHealth Translational Research Institute · 54 trials · 24% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Alcon Research · 2% recruiting · 275 trials
- Société des Produits Nestlé (SPN) · 2% recruiting · 53 trials
- Eisai · 2% recruiting · 287 trials
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
Related
What to do with this Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center page
55 registered trials is a research-attention snapshot, not an endorsement of Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center or any single study.
- 1 of Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- LET is the condition Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See LET trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center pipeline card: 55 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.